PD-L1 expression in penile cancer: a new frontier for immune checkpoint inhibitors?

被引：5
|
作者：
Al-Ahmadie, H. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷 / 09期
关键词：
NIVOLUMAB; IPILIMUMAB; CARCINOMA; PEMBROLIZUMAB; OPPORTUNITIES; BLADDER; CELLS;
D O I：
10.1093/annonc/mdw268
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1658 / 1659
页数：2
相关论文
共 50 条
  • [1] Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
    Akinleye, Akintunde
    Rasool, Zoaib
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (01)
  • [2] Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
    Akintunde Akinleye
    Zoaib Rasool
    [J]. Journal of Hematology & Oncology, 12
  • [3] Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer
    Iosune Baraibar
    Ignacio Melero
    Mariano Ponz-Sarvise
    Eduardo Castanon
    [J]. Drug Safety, 2019, 42 : 281 - 294
  • [4] Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer
    Baraibar, Iosune
    Melero, Ignacio
    Ponz-Sarvise, Mariano
    Castanon, Eduardo
    [J]. DRUG SAFETY, 2019, 42 (02) : 281 - 294
  • [5] Prospective role of PD-1/PD-L1 immune checkpoint inhibitors in GI cancer
    AmeliMojarad, Mandana
    AmeliMojarad, Melika
    Cui, Xiaonan
    [J]. PATHOLOGY RESEARCH AND PRACTICE, 2023, 244
  • [6] Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint
    Magiera-Mularz, Katarzyna
    Skalniak, Lukasz
    Zak, Krzysztof M.
    Musielak, Bogdan
    Rudzinska-Szostak, Ewa
    Berlicki, Lukasz
    Kocik, Justyna
    Grudnik, Przemyslaw
    Sala, Dominik
    Zarganes-Tzitzikas, Tryfon
    Shaabani, Shabnam
    Doemling, Alexander
    Dubin, Grzegorz
    Holak, Tad A.
    [J]. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2017, 56 (44) : 13732 - 13735
  • [7] Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers
    Duruisseaux, Michael
    Rouquette, Isabelle
    Adam, Julien
    Cortot, Alexis
    Cazes, Aurelie
    Gibault, Laure
    Damotte, Diane
    Lantuejoul, Sylvie
    [J]. ANNALES DE PATHOLOGIE, 2017, 37 (01) : 61 - 78
  • [8] PD-L1 as a biomarker of response to immune-checkpoint inhibitors
    Deborah Blythe Doroshow
    Sheena Bhalla
    Mary Beth Beasley
    Lynette M. Sholl
    Keith M. Kerr
    Sacha Gnjatic
    Ignacio I. Wistuba
    David L. Rimm
    Ming Sound Tsao
    Fred R. Hirsch
    [J]. Nature Reviews Clinical Oncology, 2021, 18 : 345 - 362
  • [9] PD-L1 as a biomarker of response to immune-checkpoint inhibitors
    Doroshow, Deborah Blythe
    Bhalla, Sheena
    Beasley, Mary Beth
    Sholl, Lynette M.
    Kerr, Keith M.
    Gnjatic, Sacha
    Wistuba, Ignacio I.
    Rimm, David L.
    Tsao, Ming Sound
    Hirsch, Fred R.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2021, 18 (06) : 345 - 362
  • [10] Efficacy of PD-1/PD-L1 Immune Checkpoint Inhibitors for Advanced NSCLC According to PD-L1 Expression: A Meta-Analysis
    Ma, K.
    Guo, Y.
    Wang, Y.
    Wang, X.
    Xu, Y.
    Sun, C.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S584 - S584
12345